ArcticZymes AS has signed a supply agreement with GE Healthcare Life Sciences for the supply of products based on ArcticZymes’ unique heat-labile enzyme portfolio.
“This agreement is another important result of our strategy to focus on the global leaders in molecular biology. We are proud to see GE Healthcare Life Sciences becoming one of our business partners in this market” says Svein Lien, CEO.
ArcticZymes’ heat-labile enzyme portfolio comprises SAP (shrimp alkaline phosphatase), Cod-UNG, DNases and other nucleases, and kits for PCR decontamination and gDNA removal. These cold-adapted enzymes are particularly well suited for molecular biological research and diagnostic markets.
This supply agreement adds GE Healthcare Life Sciences to an expanding customer base already counting leading industry names such as Affymetrix and New England Biolabs.
No financial or other deal terms are disclosed.